<DOC>
	<DOCNO>NCT01533116</DOCNO>
	<brief_summary>To investigate effect BIA 9-1067 steady-state condition levodopa pharmacokinetics</brief_summary>
	<brief_title>Effect BIA 9-1067 Steady-state Pharmacokinetics Levodopa/Carbidopa Levodopa/Benserazide</brief_title>
	<detailed_description>Single centre , randomize , double-blind , gender-balanced , placebo-controlled study 4 group healthy subject</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Benserazide</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Availability entire study period willingness adhere protocol requirement evidence informed consent form ( ICF ) duly read , sign date volunteer prior participation study . Male female volunteer . Volunteers least 25 year age old 45 year . Volunteers body mass index ( BMI ) great equal 19 30 kg/m2 . Volunteers healthy determine prestudy ( screen ) medical history , physical examination , vital sign , complete neurological examination 12lead ECG . Volunteers clinical laboratory test result judge clinically acceptable ( within laboratory 's state normal range ; within range , must without clinical significance ) screen admission first treatment period . Volunteers negative test hepatitis B surface antigen ( HBsAg ) , antihepatitis C antibody ( HCV Ab ) , Human immunodeficiency viruses 1 2 antibody ( HIV1 HIV2 Ab ) screening . Volunteers negative screen ethyl alcohol drug abuse screen admission treatment period . Volunteers non exsmokers . For purpose study , exsmoker define someone completely stop smoke least 3 month day 1 study . Due unknown risk potential harm unborn fetus , sexually active men woman must agree use medically acceptable form contraception throughout study . If female childbearing potential , negative HCG beta serum pregnancy test screen admission treatment period . The informed consent form must sign volunteer , prior participation study . Volunteers conform inclusion criterion , case Volunteers clinically relevant surgical history . Volunteers clinically relevant family history . Volunteers history relevant atopy . Volunteers significant infection know inflammatory process screen admission treatment period . Volunteers acute gastrointestinal symptom time screen admission treatment period ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Volunteers vegetarian , vegan medical dietary restriction . Volunteers could communicate reliably investigator . Volunteers unlikely cooperate requirement study . History hypersensitivity BIA 91067 , tolcapone , entacapone , levodopa , benserazide relate product ( include excipients formulation ) well severe hypersensitivity reaction ( like angioedema ) drug . Presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect . History significant gastrointestinal , liver kidney disease may affect drug bioavailability . Presence history significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , lymphatic , musculoskeletal , genitourinary , endocrine , immunologic , dermatologic connective tissue disease . Suicidal tendency , history disposition seizure , state confusion , clinically relevant psychiatric disease . Presence significant heart disease disorder accord ECG . Presence suspicious undiagnosed skin lesion history melanoma . Previous history Neuroleptic Malignant Syndrome ( NMS ) and/or nontraumatic rhabdomyolysis . History significant glaucoma . Used prescription medication include monoamine oxidase ( MAO ) inhibitor within 28 day day 1 study . Used overthecounter ( OTC ) product within 7 day day 1 study . Maintenance therapy drug , significant history drug dependency ( drug abuse ) alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) . Any clinically significant illness previous 28 day day 1 study . Volunteers take Investigational Product ( another clinical trial ) donate 50 mL blood previous 28 day day 1 study . Poor motivation , intellectual problem likely limit validity consent participate study limit ability comply protocol requirement inability cooperate adequately , inability understand observe instruction physician . Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study . Positive urine screen ethyl alcohol drug abuse admission treatment period . Any history tuberculosis and/or prophylaxis tuberculosis . Positive result HIV , HBsAg antiHCV test . Participation previous clinical study BIA 91067 . Females pregnant accord positive serum pregnancy test lactating . Females childbearing potential refuse use acceptable contraceptive regimen throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>BIA 9-1067</keyword>
</DOC>